Introduction {#S1}
============

Surgery is the standard treatment option for patients with early-stage, medically operable patients because of its known long-term efficacy ([@B1]).

The relationship between patients chosen for surgical therapy and their outcome in relation to economic, insurance, partnership, and racial issues has been infrequently studied. A recent retrospective study using the VA Central Cancer Registry in stage I/II non-small cell lung cancer (NSCLC) from 2001 to 2010 demonstrated that the disparity between Blacks and Whites receiving an operation decreased to similar rates during this time period. Furthermore, there was no survival difference between Black and Whites undergoing an operation, and no lung cancer-specific survival (LCSS) differences between races ([@B2]). Using data compiled from 38 state and the District of Columbia population-based cancer registries compiled by the North American Association of Central Cancer Registries, Sineshaw et al. demonstrated that the receipt of curative-intent surgery varied by state and was lower in blacks than whites in every state (statistically significant in Texas and Florida) ([@B3]). Similarly, using the Surveillance Epidemiology and End Reporting (SEER) database from 2007 to 2012, Taioli and Flores noted that even after adjusting by age and insurance status, blacks were less likely to receive surgery, but more likely to receive radiation than white patients ([@B4]). However, none of these studies evaluate race in relation to economic, marital, and insurance variables. Nor have these reports analyzed differences in outcome in the many different ethnic groups who are found in the United States.

Because lung cancer screening was shown to be of benefit in 2011 ([@B5]) and was approved by CMS in 2015, early-stage resectable (ESR) NSCLC is expected to increase and result in more lung cancer survivors ([@B6]). Therefore, assessing the presentation and outcomes of patients undergoing surgery for NSCLC and inter-relationship of ethnicity in regards to marital, economic, histologic, treatment, and insurance variables will be increasingly important.

The purpose of our study is to investigate the presenting characteristics of patients undergoing a definitive surgical procedure in nine different ethnic groups \[White non-Hispanic (White), Black, White Hispanic (Hispanic), American Indian/Alaskan native (AI/AN), Chinese, Japanese, Other Asian, South Asian, and Other Race\] and to assess prognosis and 90-day mortality for all surgical patients and for those presenting with early-stage, resectable tumors (ESR, \<4 cm without involved nodes). The prognostic importance of race will be determined in a multivariate model that adjusts for known histopathologic and patient-related factors as well as income, marital status, and insurance.

Materials and Methods {#S2}
=====================

Data Source {#S2-1}
-----------

Data for this study were taken from the SEER program of the National Cancer Institute, which started to collect and publish cancer incidence and survival data from population-based cancer registries in 1973. The "SEER-18" database used in this study includes registries in Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, Utah, Los Angeles, San Jose-Monterey, Rural Georgia, Greater California, Kentucky, Louisiana, New Jersey, Greater Georgia, and the Alaska Native Tumor Registry ([@B7]). Data are available from all cases diagnosed from 2000 and later for these registries. The SEER 18 sites cover approximately 28% of the American population ([@B7]).

Cohort Selection {#S2-2}
----------------

We included adults, ages who were at least 18 years old and who were diagnosed with histologically proven NSCLC in the SEER-18 database during 2007--2012.

Outcome and presenting characteristics were examined for all surgical patients (TS) (*N* = 35,689) and patients with presenting with ESR disease (*N* = 17,931) for whom sufficient information was collected to assess the outcome of treatment in relation to patient, economic, histopathologic, and insurance variables. Patients included in this investigation had NSCLC as their first primary cancer. Only microscopically confirmed tumors using NSCLC codes (8012-8014,8022,8031-8033,8046,8052,8070-8073,8082,8084,8123,8140,8200,8230,8250-8255,8260,8310,8333,8430,8470,8480-8481,8490,8550,8560,8972,8980) were included in this study.

Only patients undergoing a definitive surgical procedure without pre-operative radiation were included in this analysis. The surgical procedures defined as definitive were as follows: sublobar resection (sublobar resection; segmental resection, including lingulectomy; or wedge resection); and lobectomy or greater (lobectomy or bi-lobectomy, with or without extension to include the chest wall; lobectomy with mediastinal node dissection; extended lobectomy or bi-lobectomy, not otherwise specified; pneumonectomy with mediastinal node dissection; or pneumonectomy, not otherwise specified).

Outcome Variables and Other Covariates {#S2-3}
--------------------------------------

The outcome variables were overall survival (OS) and LCSS. Deaths from other causes were treated as censoring events. The main purpose of our investigation was to examine whether there are differences in presenting characteristics and outcomes in nine different ethnic groups by examining marital status, household income (\<\$50,000; \$50--\$74,999; \>\$75,000), type of insurance (insured, Medicaid, uninsured, unknown) in addition to established histopathologic and patient factors. Household income was listed in the SEER registry by median household income per county. The population was split into nine different ethnic groups as follows: White non-Hispanic (White), Black, White Hispanic (Hispanic), AI/AN, Chinese, Japanese, South Asian (Asian Indian and Pakistani), Other Asian (Filipino, Thai, Vietnamese, Korean, Kampuchean, Laotian, and Hmong), and Other Race (OR, Chamorran, Fiji Islander, Guamanian, Hawaiian, Melanesian, Micronesian, New Guinean, Pacific Islander, Polynesian, Samoan, Tahitian, Tongan, unknown, and other) in both the entire lung cancer surgical population as well as those presenting with ESR disease. We originally wanted to include black Hispanic patients as a separate patient category in this manuscript and its companion study assessing ethnic differences in all lung cancer patients and those with Stage IV disease, but since we wanted similar populations in both studies and because the number of Black Hispanic patients was scant in both the TS population and the ESR groups, we decided to include Black Hispanic patients in the Black category, similar to a past study ([@B8]). Black Hispanic patients represented approximately 0.6% of patient group undergoing surgical resection (19/3,276). Throughout this manuscript, the term population(s) will refer to total population of surgical patients (TS) and those with ESR disease, while group(s) will refer to the nine different ethnicities.

Variables examined for their potential effect on outcome were gender; age; year of diagnosis; marital status; race; ethnicity; tumor stage; *t*-stage, *n*-stage; nodes examined; nodes positive; node density (number of nodes positive/number of nodes examined); tumor size; histology; grade; SEER registry location; median family income; resection type; post-operative radiation; and tumor location. Median follow-up time was calculated by the methods of Schemper and Smith in which death becomes a censored follow-up time and was noted to be 36 and 35 months in the TS and ESR groups, respectively ([@B9]).

Statistical Analysis {#S2-4}
--------------------

Chi-square and *t*-test were used to compare difference between the ethnic groups with respect to treatment, patient characteristics, and tumor characteristics. Cox proportional hazards models estimates ([@B10]) were used to calculate adjusted hazard ratios with their 95% confidence intervals, and to show how treatment and other covariates were related to OS and LCSS. Medicare eligibility was controlled through use of two strata for age at diagnosis (≥65 vs \<65 years old) because individual cases will change when they enroll in Medicare. The cox proportional hazards assumption was checked by visual examination of survival plots.

Results {#S3}
=======

Presenting Characteristics {#S3-1}
--------------------------

Complete demographic and histologic details of the TS and ESR patients can be seen in Table [1](#T1){ref-type="table"}. Median age of the patients in the TS and ESR populations were both 68.0 years. There was a female predominance to both populations (50.4%---TS and 55.1%---ESR). The three largest ethnic groups in the TS were White, Black, and Hispanic, and they represented 78.6, 9.2, and 5.0% of the population, respectively. Likewise, the ESR population's three largest ethnic groups were White (79.6%), Black (8.4%), and Hispanic (4.6%). A similar proportion of patients presented with a low median family income (\<\$50,000) and was noted to be 29.8 and 28.7% in the TS and ESR populations, respectively. The majority of patients were married, 57.3% (TS) and 56.2% (ESR). 87.4% (TS) and 88.3% (ESR) patients were insured. Adenocarcinoma was the predominant histology (61.7%---TS and 67.1%---ESR).

###### 

Demographic characteristics of both the TS and early-stage resectable patients.

                                                                       All surgical (*N* **=** 35,689)   Favorable (*N* **=** 17,931)
  -------------------------------------------------------------------- --------------------------------- ------------------------------
  **Age---years**                                                                                        
  Median                                                               68.0                              68.0
                                                                                                         
  **Sex---no. (%**)                                                                                      
  Female                                                               (50.4%) 17,989                    (55.1%) 9,882
  Male                                                                 (49.6%) 17,700                    (44.9%) 8,693
                                                                                                         
  **Race---no. (%**)                                                                                     
  White Hispanic                                                       (4.98%) 1,779                     (4.60%) 823
  White non-Hispanic                                                   (78.60%) 28,052                   (79.60%) 14,273
  Black                                                                (9.18%) 3,276                     (8.42%) 1,509
  Chinese                                                              (1.59%) 568                       (1.61%) 288
  Japanese                                                             (0.85%) 302                       (0.78%) 139
  South Asian                                                          (0.31%) 112                       (0.31%) 56
  Other Asian                                                          (2.83%) 1,011                     (2.96%) 531
  Other Race                                                           (1.28%) 457                       (1.41%) 252
  American Indian/Alaskan Native                                       (0.37%) 132                       (0.33%) 60
                                                                                                         
  **Surveillance Epidemiology and End Reporting Registry---no. (%)**                                     
  Alaska Natives                                                       (0.10%) 35                        (0.07%) 13
  Atlanta                                                              (3.05%) 1,090                     (2.79%) 501
  California excl SF/SJM/LA                                            (19.24%) 6,865                    (19.63%) 3,521
  Connecticut                                                          (5.99%) 2,138                     (6.44%) 1,155
  Detroit                                                              (6.23%) 2,223                     (6.40%) 1,148
  Greater Georgia                                                      (9.45%) 3,374                     (9.46%) 1,696
  Hawaii                                                               (1.54%) 549                       (1.56%) 279
  Iowa                                                                 (4.32%) 1,544                     (4.10%) 736
  Kentucky                                                             (9.90%) 3,534                     (9.56%) 1,715
  Los Angeles                                                          (7.64%) 2,728                     (7.38%) 1,324
  Louisiana                                                            (5.54%) 1,977                     (5.15%) 924
  New Jersey                                                           (13.34%) 4,760                    (13.92%) 2,496
  New Mexico                                                           (1.41%) 503                       (1.42%) 254
  Rural Georgia                                                        (0.23%) 83                        (0.23%) 42
  San Francisco-Oakland                                                (4.47%) 1,594                     (4.51%) 809
  San Jose-Monterey                                                    (2.14%) 762                       (1.94%) 347
  Seattle                                                              (4.08%) 1,457                     (4.34%) 779
  Utah                                                                 (1.33%) 473                       (1.07%) 192
                                                                                                         
  **Income---no. (%)**                                                                                   
  \<50k                                                                (29.84%) 10,649                   (28.67%) 5,140
  50k--74k                                                             (52.88%) 18,871                   (53.40%) 9,575
  ≥75k                                                                 (17.29%) 6,169                    (17.94%) 3,216
                                                                                                         
  **Marital status---no. (%)**                                                                           
  Divorced                                                             (12.13%) 4,330                    (12.06%) 2,162
  Married                                                              (57.33%) 20,460                   (56.19%) 10,076
  Separated                                                            (0.98%) 350                       (0.91%) 163
  Single                                                               (11.23%) 4,009                    (10.75%) 1,927
  Unknown                                                              (3.52%) 1,258                     (3.89%) 698
  Domestic partner                                                     (0.09%) 33                        (0.06%) 11
  Widowed                                                              (14.71%) 5,249                    (16.14%) 2,894
                                                                                                         
  **AJCC T 6th edition---no. (%)**                                                                       
  T0                                                                   (0.03%) 9                         0
  T1                                                                   (41.75%) 14,900                   (69.25%) 12,417
  T2                                                                   (42.36%) 15,119                   (30.75%) 5,514
  T3                                                                   (5.63%) 2,010                     0
  T4                                                                   (9.91%) 3,537                     0
  TX                                                                   (0.32%) 114                       0
                                                                                                         
  **Insurance---no. (%)**                                                                                
  Insured                                                              (87.45%) 31,210                   (88.26%) 15,826
  Medicaid                                                             (9.85%) 3,516                     (9.48%) 1,700
  Uninsured                                                            (2.07%) 740                       (1.63%) 292
  Unknown                                                              (0.62%) 223                       (0.63%) 113
                                                                                                         
  **Lateral location---no. (%)**                                                                         
  Bronchus, left                                                       (0.38%) 136                       (0.09%) 16
  Bronchus, right                                                      (0.32%) 116                       (0.06%) 11
  Bronchus, unknown                                                    (0.03%) 9                         (0.02%) 3
  Left lower                                                           (13.95%) 4,980                    (13.76%) 2,467
  Left upper                                                           (26.30%) 9,388                    (26.14%) 4,687
  Left NOS                                                             (0.69%) 248                       (0.31%) 56
  Left overlapping                                                     (0.36%) 127                       (0.12%) 22
  Lung, NOS                                                            (0.22%) 80                        0
  Right lower                                                          (17.45%) 6,228                    (17.30%) 3,102
  Right middle                                                         (5.00%) 1,786                     (5.50%) 986
  Right upper                                                          (32.99%) 11,774                   (35.71%) 6,404
  Right NOS                                                            (1.14%) 407                       (0.45%) 81
  Right overlapping                                                    (1.15%) 410                       (0.54%) 96
                                                                                                         
  **Histology---no. (%)**                                                                                
  Adenocarcinoma                                                       (61.74%) 22,037                   (67.12%) 12,036
  Adenosquamous                                                        (2.86%) 1,021                     (2.44%) 438
  Large cell                                                           (3.01%) 1,075                     (2.53%) 454
  Non-small cell                                                       (3.72%) 1,327                     (2.76%) 495
  Other                                                                (0.99%) 355                       (0.73%) 131
  Squamous                                                             (27.67%) 9,874                    (24.41%) 4,377
                                                                                                         
  **Grade---no. (%)**                                                                                    
  Moderately, II                                                       (41.20%) 14,703                   (45.29%) 8,121
  Poorly, III                                                          (36.31%) 12,960                   (28.56%) 5,121
  Undifferentiated, IV                                                 (1.96%) 701                       (1.39%) 250
  Unknown                                                              (6.94%) 2,476                     (5.64%) 1,012
  Well, I                                                              (13.59%) 4,849                    (19.11%) 3,427
                                                                                                         
  **Surgical Procedure---no. (%)**                                                                       
  (Bi)Lobectomy                                                        (76.16%) 27,182                   (76.79%) 13,769
  Penumonectomy                                                        (5.52%) 1,971                     (0.94%) 169
  Segmentectomy                                                        (3.04%) 1,084                     (4.06%) 728
  Sub-lobar resection, NOS                                             (0.62%) 222                       (0.41%) 74
  Wedge                                                                (14.65%) 5,230                    (17.80%) 3,191
                                                                                                         
  **Radiation---no. (%)**                                                                                
  No                                                                   (85.23%) 30,419                   (96.77%) 17,352
  Yes                                                                  (14.77%) 5,270                    (3.23%) 579
                                                                                                         
  **Year of diagnosis---no. (%)**                                                                        
  2007                                                                 (17.03%) 6,077                    (16.81%) 3,015
  2008                                                                 (17.10%) 6,103                    (16.90%) 3,030
  2009                                                                 (16.99%) 6,062                    (17.22%) 3,087
  2010                                                                 (16.67%) 5,949                    (16.83%) 3,018
  2011                                                                 (16.44%) 5,868                    (16.63%) 2,982
  2012                                                                 (15.78%) 5,630                    (15.61%) 2,799

Univariate Analysis of All Patients Undergoing Surgical Resection of Lung Cancer {#S3-2}
--------------------------------------------------------------------------------

Table [2](#T2){ref-type="table"} contains the demographic, histologic, and treatment details for the TS population for the nine different ethnic groups and used the White population as the reference group. Blacks presented with a younger age, less stage I tumors, less grade I tumors, lower income, higher percentage of adenocarcinomas, less nodes examined, and were less likely to be insured, but their number of nodes positive, nodal density, OS, and LCSS was the same. Their 30 and 90-day mortality did not differ as compared to Whites. Hispanic patients presented with younger age, higher median household income, lower rates of insurance, higher percentage of females, lower percentage of Stage I, more grade 1 tumors, higher percentage of adenocarcinomas, and had less nodes examined, but they had a similar number of nodes positive, nodal density, OS and LCSS. Hispanics had a similar 90-day mortality, but their 30-day mortality was higher than Whites (mean 1.8 vs 1.1%). Of all the ethnic groups, the Japanese presented with a highest mean age (70.9), the highest female predominance (62.3%), and the highest rates of insurance (98.0%), but there was a similar OS and LCSS to Whites. Blacks (58.3%) and Hispanics (59.2%) presented with a lower proportion of patients with Stage I NSCLC as compared to Whites (63.2%), but similar rates were noted in all other ethnic groups. The Other Asian group presented with the highest percentage of adenocarcinomas (78.5%), while American/Alaskan Natives presented with the highest percentage of squamous cell carcinomas (35.6%). The Chinese had the highest proportion of patients receiving a (bi)lobectomy at 86.1%, but the least receiving a pneumonectomy (2.5%) as well as a wedge resection (8.8%). Likewise, the Chinese were least likely to undergo a sub-lobar resection for tumors greater than 2 cm with only 5.0% receiving such treatment. Blacks (8.2), Hispanics (8.5), and Other Asians (8.3) were found to have less mean nodes examined than Whites (9.0), and a higher proportion of patients with positive nodes was noted in the Other Asian group (26 vs 21.8%), but none of the other ethnic groups differed from Whites in terms of the median number of nodes explored or number of nodes positive. The only ethnic group that differed from Whites in regards to nodal density was the Other Asian group, 0.10-Other Asians vs 0.07-Whites. The 30-day mortality was higher in the Hispanic patients, but lower in the Other Race and Japanese ethnic groups. The 90-day survival was significantly higher in the Other Race and Other Asian groups. As compared to Whites, OS and LCSS was significantly greater in the Chinese, South Asian, Other Asian, and the Other Race groups. Unadjusted OS by ethnic group can be found in the Kaplan--Meier survival in Figure [1](#F1){ref-type="fig"}A.

###### 

Demographic, histologic, and treatment details in the TS population for the nine different ethnic groups.

  *N* = 35,689                        White non-Hispanic   White Hispanic          Black                   Chinese                 Japanese                 South Asian             Other Asian             Other Race               American Indian/Alaskan
  ----------------------------------- -------------------- ----------------------- ----------------------- ----------------------- ------------------------ ----------------------- ----------------------- ------------------------ -------------------------
  Patient numbers                     28,052               1,779                   3,276                   568                     302                      112                     1,011                   457                      132
  **Age at diagnosis, years**                                                                                                                                                                                                        
  Mean (95% CI)                       67.4 (67.3--67.5)    **66.1 (65.5--66.6)**   **63.2 (62.8--63.5)**   66.9 (66.0--67.8)       **70.9 (69.7--72.0)**    **64.3 (62.1--66.6)**   **65.8 (65.2--66.5)**   **64.4 (63.4--65.4)**    **63.7 (62.1--65.4)**
  Median (range)                      68 (6--85)           68 (4--85)              63 (12--85)             68 (23--85)             73 (33--85)              65 (8--85)              67 (29--85)             66 (20--85)              64 (40--85)
                                                                                                                                                                                                                                     
  **Insurance, % (95% CI)**                                                                                                                                                                                                          
  Insured                             90.1 (89.8--90.5)    **76.5 (74.5--78.5)**   **76.6 (75.1--78.0)**   **76.6 (73.1--80.1)**   **98.0 (96.4--99.6)**    **71.4 (62.9--79.9)**   **75.9 (73.2--78.5)**   **83.6 (80.2--87.0)**    **70.5 (62.6--78.3)**
  Medicaid                            7.5 (7.2--7.8)       **20.1 (18.3--22.0)**   **18.3 (17.0--19.6)**   **21.7 (18.3--25.1)**   **1.3 (0.0--2.6)**       **21.4 (13.7--29.1)**   **21.4 (18.8--23.9)**   **13.1 (10.0--16.2)**    **25.8 (18.2--33.3)**
  Uninsured                           1.8 (1.7--2.0)       **2.4 (1.7--3.1)**      **4.0 (3.3--4.6)**      1.2 (0.3--2.1)          **0.3 (0.0--1.0)**       6.2 (1.7--10.8)         2.7 (1.7--3.7)          2.4 (1.0--3.8)           0.8 (0.0--2.3)
  Unknown                             0.5 (0.5--0.6)       1.0 (0.5--1.4)          **1.2 (0.8--1.5)**      0.5 (0.0--1.0)          0.3 (0.0--1.0)           0.9 (0.0--2.7)          **0.1 (0.0--0.3)**      0.9 (0.0--1.7)           3.0 (0.1--6.0)
                                                                                                                                                                                                                                     
  **Income, % (95% CI)**                                                                                                                                                                                                             
  \<50K                               31.6 (31.1--32.2)    **18.3 (16.5--20.1)**   **40.5 (38.8--42.1)**   **1.8 (0.7--2.8)**      **2.6 (0.8--4.5)**       **6.5 (2.3--12.0)**     **4.3 (3.0--5.5)**      **5.3 (3.2--7.3)**       **24.2 (16.8--31.6)**
  50K--74K                            51.3 (50.8--51.9)    **61.8 (59.6--64.1)**   50.7 (49.0--52.4)       54.8 (50.6--58.9)       **87.4 (83.7--91.2)**    46.4 (37.0--55.8)       **66.0 (63.0--68.9)**   **70.0 (65.8--74.2)**    **70.5 (62.6--78.3)**
  \>75K                               17.0 (16.6--17.5)    **19.8 (18.0--21.7)**   **8.8 (7.8--9.7)**      **43.5 (39.4--47.6)**   **9.9 (6.5--13.3)**      **46.4 (37.0--55.8)**   **29.8 (26.9--32.6)**   **24.7 (20.8--28.7)**    **5.3 (1.4--9.2)**
                                                                                                                                                                                                                                     
  **Sex, % (95% Cl)**                                                                                                                                                                                                                
  Female                              50.0 (49.4--50.6)    **54.5 (52.2--56.8)**   51.4 (49.7--52.6)       47.7 (43.6--51.8)       **62.3 (56.8--67.7)**    42.0 (32.7--51.2)       49 (45.9--52.0)         54.3 (49.7--58.9)        47.7 (39.1--56.3)
  Male                                50.0 (49.4--50.6)    **45.5 (43.2--47.8)**   48.6 (46.9--50.3)       52.3 (48.2--56.4)       **37.7 (32.2--43.2)**    58.0 (48.8--67.3)       51.0 (48.0--54.1)       45.7 (41.1--50.3)        52.3 (43.6--60.9)
                                                                                                                                                                                                                                     
  **Marital Status**                                                                                                                                                                                                                 
  Married (including common law)      58.9 (58.3--59.5)    **54.2 (51.9--56.6)**   **37.2 (35.5--38.8)**   **74.6 (71.1--78.2)**   63.6 (58.1--69.0)        **73.2 (66.9--81.5)**   **71.1 (68.3--73.9)**   60.0 (56.4--64.5)        50.0 (41.4--58.6)
  Single (never married)              9.5 (9.1--9.8)       **15.3 (13.7--17.0)**   **26.8 (25.3--28.3)**   **6.7 (4.6--8.8)**      **6.0 (3.3--8.6)**       8.9 (3.6--14.3)         7.6 (6.0--9.3)          10.1 (7.3--12.8)         12.1 (7.2--17.9)
  Widowed                             15.1 (14.7--15.6)    14.6 (12.9--16.2)       **12.9 (11.8--14.1)**   **9.2 (6.8--11.5)**     19.9 (15.3--24.4)        **5.4 (1.1--9.6)**      **12.1 (10.1--14.1)**   14.2 (11.0--17.4)        12.1 (7.2--17.9)
  Other                               16.5 (16.1--17.0)    15.9 (14.2--17.6)       **23.0 (21.6--24.5)**   **9.5 (7.1--11.9)**     **10.6 (7.1--14.1)**     12.5 (6.3--18.7)        **9.2 (7.4--11.0)**     15.8 (12.4--19.1)        **25.8 (18.2--33.3)**
                                                                                                                                                                                                                                     
  **Stage, % (95% CI)**                                                                                                                                                                                                              
  1                                   63.2 (62.6--63.7)    **59.2 (56.9--61.5)**   **58.3 (56.6--60.0)**   61.3 (57.2--65.3)       59.3 (53.7--64.8)        65.2 (56.2--74.1)       61.7 (58.7--64.7)       66.3 (62.0--70.7)        56.1 (47.5--64.6)
  2                                   12.9 (12.5--13.3)    12.5 (10.9--14.0)       **14.5 (13.3--15.7)**   11.8 (9.1--14.5)        11.9 (8.2--15.6)         **7.1 (2.3--12.0)**     11.3 (9.3--13.2)        12.9 (9.8--16.0)         17.4 (10.9--24.0)
  3                                   17.0 (16.6--17.5)    18.5 (16.7--20.4)       **19.0 (17.7--20.4)**   17.4 (14.3--20.6)       20.5 (15.9--25.1)        22.3 (14.5--30.2)       **20.2 (17.7--22.7)**   15.8 (12.4--19.1)        22.0 (14.8--29.1)
  4                                   6.9 (6.6--7.2)       **9.8 (8.4--11.2)**     8.1 (7.1--9.1)          9.5 (7.1--11.9)         8.3 (5.2--11.4)          5.4 (1.1--9.6)          6.8 (5.3--8.4)          5.0 (3.0--7.0)           4.5 (0.9--8.1)
                                                                                                                                                                                                                                     
  **Histology, % (95% CI)**                                                                                                                                                                                                          
  Adenocarcinoma                      60.2 (59.6--60.7)    **66.9 (64.8--69.1)**   **62.6 (61.0--64.3)**   **78.3 (74.9--81.7)**   **66.9 (61.5--72.2)**    **77.7 (69.8--85.5)**   **78.5 (76.0--81.1)**   **71.8 (67.6--75.9)**    **47.0 (38.3--55.6)**
  Adenosquamous                       2.9 (2.7--3.1)       3.4 (2.6--4.3)          2.9 (2.3--3.5)          2.8 (1.5--4.2)          3.0 (1.1--4.9)           **0.9 (0.0--2.7)**      2.2 (1.3--3.1)          1.8 (0.5--3.0)           3.8 (0.5--7.1)
  Large cell                          3.1 (2.9--3.3)       2.4 (1.7--3.1)          3.6 (3.0--4.3)          2.5 (1.2--3.7)          3.3 (1.3--5.3)           5.4 (1.1--9.6)          **1.2 (0.5--1.9)**      2.0 (0.7--3.2)           4.5 (0.9--8.1)
  Non-small cell                      3.7 (3.5--3.9)       (2.3--3.7)              **5.4 (4.6--6.1)**      2.6 (1.3--4.0)          2.3 (0.6--4.0)           2.7 (0.0--5.7)          **2.0 (1.1--2.8)**      **1.8 (0.5--3.0)**       8.3 (3.6--13.1)
  Others                              0.9 (0.8--1.1)       **1.7 (1.1--2.4)**      1.1 (0.7--1.4)          1.1 (0.2--1.9)          0.7 (0.0--1.6)           0.9 (0.0--2.7)          0.7 (0.2--1.2)          2.0 (0.7--3.2)           0.8 (0.0--2.3)
  Squamous                            29.3 (28.7--29.8)    **22.7 (20.8--24.7)**   **24.4 (22.9--25.9)**   **12.7 (9.9--15.4)**    **23.8 (19.0--28.7)**    **12.5 (6.3--18.7)**    **15.4 (13.2--17.7)**   **20.8 (17.1--24.5)**    35.6 (27.3--43.9)
                                                                                                                                                                                                                                     
  **Surgical category, % (95% CI)**                                                                                                                                                                                                  
  (Bi)Lobectomy                       75.7 (75.2--76.2)    76.5 (74.5--78.5)       75.8 (74.3--77.2)       **86.1 (83.2--88.9)**   80.4 (76.0--85.0)        80.4 (72.9--87.8)       **81.4 (79.0--83.8)**   77.9 (74.1--81.7)        77.3 (70.0--84.5)
  Pneumonectomy                       5.7 (5.4--6.0)       5.5 (4.4--6.5)          5.4 (4.6--6.2)          **2.5 (1.2--3.7)**      3.6 (1.5--5.8)           3.6 (0.1--7.1)          **3.9 (2.7--5.0)**      4.6 (2.7--6.5)           9.1 (4.1--14.1)
  Segmentectomy                       3.1 (2.9--3.3)       3.2 (2.4--4.0)          2.9 (2.3--3.4)          2.3 (1.1--3.5)          3.6 (1.5--5.8)           **0.9 (0.0--2.7)**      2.7 (1.7--3.7)          **1.8 (0.5--3.0)**       2.3 (0.0--4.8)
  Sub-lobar resection, NOS            0.6 (0.5--0.7)       0.9 (0.5--1.3)          1.0 (0.6--1.3)          0.4 (0.0--0.8)          0.7 (0.0--1.6)           0.9 (0.0--2.7)          0.5 (0.1--0.9)          1.1 (0.1--2.1)           NA
  Wedge Resection                     14.9 (14.5--15.4)    13.9 (12.3--15.6)       15.0 (13.8--16.2)       **8.8 (6.5--11.1)**     11.6 (8.0--15.2)         14.3 (7.7--20.9)        **11.6 (9.6--13.5)**    14.7 (11.4--17.9)        11.4 (5.9--16.8)
                                                                                                                                                                                                                                     
  **Sub-lober \> 2 cm, % (95% CI)**                                                                                                                                                                                                  
  No                                  92.6 (92.3--92.9)    (91.5--93.8)            (91.3--93.1)            **95.0 (93.3--96.7)**   (89.4--95.2)             (87.0--96.8)            (91.3--94.4)            (92.7--96.7)             (91.1--98.3)
  Yes                                 7.4 (7.1--7.7)       7.4 (6.2--8.5)          7.8 (6.9--8.7)          **5.0 (3.3--6.7)**      7.7 (4.8--10.6)          8.1 (3.2--13.0)         7.1 (5.6--8.7)          5.3 (3.3--7.3)           5.3 (1.7--8.9)
                                                                                                                                                                                                                                     
  **Number of nodes examined**                                                                                                                                                                                                       
  Mean (95% CI)                       9.0 (8.9--9.1)       **8.5 (8.2--8.9)**      **8.2 (8.0--8.5)**      9.0 (8.3--9.7)          9.0 (8.1--9.8)           9.9 (8.0--11.8)         **8.3 (7.8--8.7)**      8.6 (7.9--9.3)           8.3 (6.7--9.9)
  Median (range)                      7 (0--90)            7 (0--87)               6 (0--90)               7 (0--90)               7 (0--44)                6.5 (0--68)             6 (0--60)               7 (0--67)                6 (0--54)
                                                                                                                                                                                                                                     
  **Number of nodes positive**                                                                                                                                                                                                       
  Mean (95% CI)                       0.6 (0.6--0.7)       0.7 (0.6--0.7)          0.6 (0.6--0.7)          0.7 (0.5--0.9)          0.8 (0.6--1.1)           0.8 (0.4--1.2)          0.7 (0.6--0.9)          0.8 (0.6--0.9)           0.8 (0.5--1.2)
  Median (range)                      0 (0--61.0)          0 (0--26.0)             0 (0--29.0)             0 (0--28.0)             0 (0--21.0)              0 (0--13.0)             0 (0--16.0)             0 (0--24.0)              0 (0--17.0)
                                                                                                                                                                                                                                     
  **Node positivity, % (95% CI)**                                                                                                                                                                                                    
  No                                  78.2 (77.7--78.6)    77.5 (75.6--79.5)       76.7 (75.3--78.1)       74.5 (70.9--78.1)       73.8 (68.9--78.8)        75.9 (67.8--83.9)       **(71.3--76.7)**        76.8 (72.9--80.7)        74.2 (66.7--81.8)
  Yes                                 21.8 (21.4--22.3)    22.5 (20.5--24.4)       23.3 (21.9--24.7)       25.5 (21.9--29.1)       26.2 (21.2--31.1)        24.1 (16.1--32.2)       **26.0 (23.3--28.7)**   23.2 (19.3--27.1)        25.8 (18.2--33.3)
                                                                                                                                                                                                                                     
  **Node density**                                                                                                                                                                                                                   
  Mean (95% CI) (0.06--0.07)          0.07 (0.06--0.07)    0.08 (0.07--0.09)       0.08 (0.07--0.08)       0.09 (0.07--0.11)       0.08 (0.06--0.10)        0.08 (0.04--0.11)       **0.10 (0.08--0.11)**   0.08 (0.07--0.10)        0.08 (0.05--0.10)
  Median (range)                      0 (0--1.0)           0 (0--1.0)              0 (0--1.0)              0 (0--1.0)              0 (0--1.0)               0 (0--1.0)              0 (0--1.0)              0 (0--1.0)               0 (0--0.9)
                                                                                                                                                                                                                                     
  **30-day survival, % (95% CI)**                                                                                                                                                                                                    
  No                                  1.1 (1.0--1.2)       **1.8 (1.2--2.4)**      1.1 (0.7--1.4)          1.1 (0.2--1.9)          **0.3 (0.0--1.0)**       3.3 (0.1--6.4)          1.3 (0.6--2.0)          **0.2 (0.0--0.7)**       3.1 (0.1--6.0)
  Yes                                 98.9 (98.8--99.0)    **98.2 (97.6--98.8)**   98.9 (98.6--99.3)       98.9 (98.1--99.8)       **99.7 (99.0--100.0)**   100.0 (93.6--99.9)      98.7 (98.0--99.4)       **99.8 (99.3--100.0)**   96.9 (94.0--100.0)
                                                                                                                                                                                                                                     
  **90-day survival, % (95% CI)**                                                                                                                                                                                                    
  No                                  4.1 (3.9--4.4)       5.2 (4.1--6.3)          4.0 (3.3--4.7)          2.8 (1.4--4.2)          2.4 (0.6--4.2)           1.9 (0.0--4.5)          **2.7 (1.7--3.7)**      **1.9 (0.6--3.2)**       6.9 (2.5--11.3)
                                                                                                                                                                                                                                     
  **Cancer death, % (95% CI)**                                                                                                                                                                                                       
  No                                  76.6 (76.1--77.1)    77.7 (75.7--79.6)       76.1 (74.7-- 77.6)      **82.7 (79.6--85.9)**   75.8 (71.0--80.7)        **85.7 (79.1--92.3)**   **81.1 (78.7--83.5)**   **84.9 (81.6--88.2)**    81.1 (74.3--87.8)
  Yes                                 23.4 (22.9--23.9)    22.3 (20.4--24.3)       23.8 (22.4--25.3)       **17.3 (14.1--20.4)**   24.2 (19.3--29.0)        14.3 (7.7--20.3)        **18.9 (16.5--21.3)**   **15.1 (11.8--18.4)**    18.9 (12.2--25.7)
                                                                                                                                                                                                                                     
  **Other cause death, % (95% CI)**                                                                                                                                                                                                  
  No                                  91.9 (91.6--92.2)    **93.5 (92.4--94.7)**   92.4 (91.5--93.3)       **94.9 (93.1--96.7)**   91.4 (88.2--94.6)        94.6 (90.4--98.9)       **94.0 (92.5--95.4)**   **95.0 (93.0--97.0)**    90.9 (85.9--95.9)
  Yes                                 8.1 (7.8--8.4)       **6.5 (5.3--7.6)**      7.6 (6.7--8.5)          **5.1 (3.3--6.9)**      8.6 (5.4--11.8)          5.4 (1.1--9.6)          **6.0 (4.6--7.5)**      **5.0 (3.0--7.0)**       9.1 (4.1--14.1)

*95% confident intervals are given in parentheses. W is used as reference population. All characteristics differing from the W are in bold-print and have brown colored backgrounds. Otherwise, green and blue depict individual rows are different colors for ease of visualization*.

![**(A)** Unadjusted overall survival (OS) by ethnic group in the TS population. **(B)** Multivariable adjusted OS by ethnic group in the TS population.](fonc-08-00146-g001){#F1}

OS in the Total Surgical Population {#S3-3}
-----------------------------------

Multivariable analysis (MVA) for OS for TS population can be seen in Table [3](#T3){ref-type="table"}. Age (*p* \< 0.0001, HR = 1.029) and male sex (*p* \< 0.0001, HR = 1.453) were significantly associated with OS. OS was significantly better than Whites (HR = 0.693--0.843) in all groups except for AI/ANs, Japanese, Blacks, and Hispanics who had a similar OS. MVA-adjusted OS by ethic group can be seen in Figure [1](#F1){ref-type="fig"}B. As compared to Connecticut, worse survival was noted in California, Greater Georgia, Iowa, Kentucky, Louisiana, and Utah. OS was not income dependent. Insured patients had a better OS than those on Medicaid (*p* \< 0.0001, HR = 1.286). Married patients had a better OS than divorced (*p* \< 0.0001, HR = 1.191), widowed (*p* \< 0.0001, HR = 1.229), and single patients (*p* \< 0.0001, HR = 1.1215). As compared to Stage I, Stages II--IV were associated with a worse OS with a progressively increasing HR (all *p* \< 0.0001, HR = 1.702--3.273). As compared to patients with adenocarcinoma, all histologies were associated with a worse OS (*p* \< 0.0001 to \<0.0008, HR = 1.119--1.564). Using well-differentiated tumors as a reference, all other tumor grades were associated with a worse OS (all *p* \< 0.0001, HR = 1.665--3.273). Segmentectomies and (bi)lobectomies were associated with a better OS than pneumonectomies, *p* = 0.0011, HR = 0.80; *p* \< 0.0001, HR = 0.72, respectively. Patients who received radiation (*p* \< 0.0001, HR = 1.162) experienced worse OS. Number of nodes examined was associated with better OS (*p* \< 0.0001, HR = 0.988), but number of nodes positive (*p* \< 0.0001, HR = 1.04) and lymph node density (*p* \< 0.0001, HR = 1.429) were associated with worse OS. Compared to year 2007, those patients diagnosed in 2010--2012 had significantly better OS with progressively decreasing hazard ratios. OS by insurance status can be seen in Figure [2](#F2){ref-type="fig"}.

###### 

Multivariate analysis of overall survival in the TS population.

  All surgical (*N* **=** 35,689)                            *p*-Value   Hazard ratio
  ---------------------------------------------------------- ----------- --------------
  Age---years                                                \<0.0001    1.029
                                                                         
  **Sex**                                                                
  Female                                                     --          1
  Male                                                       \<0.0001    1.453
                                                                         
  **Race**                                                               
  White Hispanic                                             0.49        0.968
  White non-Hispanic                                         --          1
  Black                                                      0.46        1.026
  Chinese                                                    \<0.0001    0.693
  Japanese                                                   0.06        1.027
  South Asian                                                0.01        0.843
  Other Asian                                                0.01        0.843
  Other Race                                                 0.02        0.772
  American Indian/Alaskan Native                             0.74        1.065
                                                                         
  **Surveillance Epidemiology and End Reporting Registry**               
  Alaska Natives                                             0.72        0.873
  Atlanta                                                    0.40        1.062
  California excl SF/SJM/LA                                  0.001       1.167
  Connecticut                                                --          1
  Detroit                                                    0.95        0.996
  Greater Georgia                                            0.0005      1.217
  Hawaii                                                     0.33        1.102
  Iowa                                                       0.01        1.176
  Kentucky                                                   0.0001      1.249
  Los Angeles                                                0.06        1.111
  Louisiana                                                  0.004       1.198
  New Jersey                                                 0.12        1.081
  New Mexico                                                 0.22        1.127
  Rural Georgia                                              0.82        1.049
  San Francisco-Oakland                                      0.12        1.107
  San Jose-Monterey                                          0.49        1.059
  Seattle                                                    0.07        1.126
  Utah                                                       0.008       1.269
                                                                         
  **Income**                                                             
  \<\$50,000                                                 0.05        1.06
  \$50,000--75,000                                           --          1
  \>75,000                                                   0.24        0.963
                                                                         
  **Marital status**                                                     
  Divorced                                                   \<0.0001    1.191
  Married                                                    --          1
  Separated                                                  0.18        1.144
  Single                                                     \<0.0001    1.215
  Unknown                                                    0.05        1.118
  Domestic partner                                           0.67        0.783
  Widowed                                                    \<0.0001    1.229
                                                                         
  **Stage**                                                              
  I                                                          --          1
  II                                                         \<0.0001    1.702
  III                                                        \<0.0001    1.867
  IV                                                         \<0.0001    3.273
                                                                         
  **Insurance**                                                          
  Insured                                                    --          1
  Medicaid                                                   \<0.0001    1.286
  Uninsured                                                  0.08        1.135
  Unknown                                                    0.33        1.286
                                                                         
  **Lateral location**                                                   
  Bronchus, Left                                             0.92        1.014
  Bronchus, right                                            0.01        1.42
  Bronchus, unknown                                          0.33        0.613
  Left lower                                                 0.08        1.056
  Left upper                                                 0.10        1
  Left NOS                                                   0.04        1.211
  Left overlapping                                           0.15        0.801
  Lung, NOS                                                  \<0.0001    2.061
  Right lower                                                \<0.0001    1.23
  Right middle                                               0.75        1.015
  Right upper                                                --          1
  Right NOS                                                  0.45        1.062
  Right overlapping                                          \<0.0001    1.371
                                                                         
  **Histology---no. (%)**                                                
  Adenocarcinoma                                             --          1
  Adenosquamous                                              0.0008      1.196
  Large cell                                                 \<0.0001    1.348
  Non-small cell                                             0.0003      1.174
  Other                                                      \<0.0001    1.564
  Squamous                                                   \<0.0001    1.159
                                                                         
  **Grade**                                                              
  Moderately, II                                             \<0.0001    1.702
  Poorly, III                                                \<0.0001    1.867
  Undifferentiated, IV                                       \<0.0001    3.273
  Unknown                                                    \<0.0001    1.665
  Well, I                                                    --          1
                                                                         
  **Surgical procedure**                                                 
  (Bi)Lobectomy                                              \<0.0001    0.721
  No surgery                                                             
  Pneumonectomy                                              --          1
  Segmentectomy                                              0.0011      0.800
  Sub-lobar resection, NOS                                   0.13        1.172
  Wedge                                                      0.63        0.978
                                                                         
  Radiation post-operative                                   \<0.0001    1.162
  Number of nodes examined                                   \<0.0001    0.988
  Number of nodes positive                                   \<0.0001    1.04
  Node density                                               \<0.0001    1.429
                                                                         
  **Year of diagnosis---no. (%)**                                        
  2007                                                       --          1
  2008                                                       0.95        1.002
  2009                                                       0.28        0.969
  2010                                                       0.02        0.927
  2011                                                       0.0018      0.888
  2012                                                       \<0.0001    0.787

![Multivariable adjusted overall survival by insurance type in TS population.](fonc-08-00146-g002){#F2}

OS in the ESR Population {#S3-4}
------------------------

Multivariable analysis for OS for ESR population can be seen in Table [4](#T4){ref-type="table"}. Age (*p* \< 0.0001, HR = 1.034), and male sex (*p* \< 0.0001, HR = 1.506) were significantly associated with OS. OS was significantly better than Whites in the Other Race (*p* = 0.0051, HR = 0.555) and Other Asian groups (*p* = 0.012, HR = 0.736), but it was similar in all other ethnic groups. As compared to Connecticut, worse survival was noted in California, Greater Georgia, Kentucky, Louisiana, and Utah. OS was not income dependent. Insured patients had a better OS than those on Medicaid (*p* \< 0.0001, HR = 1.385). Married patients had a better OS than divorced (*p* \< 0.0001, HR = 1.301), widowed (*p* \< 0.0001, HR = 1.292), and single patients (*p* = 0.0015, HR = 1.121). Increasing tumor size (*p* \< 0.0001, HR = 1.016) and T2 vs T1 (*p* \< 0.0129, HR = 1.107) had a worse OS. Only the right lower lobe location was associated with survival (*p* \< 0.0089, HR = 1.132). In comparison to patients with adenocarcinoma, large cell carcinoma, NSCLC-NOS, and squamous cell carcinoma were associated with a worse OS (*p* \< 0.0011 to \<0.0001, HR = 1.15--1.381). Using well-differentiated tumors as a reference, all other tumor grades were associated with a worse OS (HR = 1.572--1.846). Segmentectomies (*p* \< 0.0090, HR = 1.235), pneumonectomies (*p* \< 0.0001, HR = 1.782), and wedge resections (*p* \< 0.0001, HR = 1.301) were associated with a worse OS than (bi)lobectomies. Patients who received radiation (*p* \< 0.0001, HR = 1.36) experienced worse OS. Number of nodes examined was associated with better OS (*p* \< 0.0001, HR = 0.984). Compared to year 2007, those patients diagnosed in 2010 and 2012 had significantly better OS.

###### 

Multivariate analysis for overall survival in early-stage resectable population.

  Early-stage resectable (*N* **=** 17,931)                  *p*-Value   Hazard ratio
  ---------------------------------------------------------- ----------- --------------
  Age---years                                                \<0.0001    1.034
                                                                         
  **Sex**                                                                
  Female                                                     --          1
  Male                                                       \<0.0001    1.506
                                                                         
  **Race**                                                               
  White Hispanic                                             0.08        0.856
  White non-Hispanic                                         --          1
  Black                                                      0.80        0.984
  Chinese                                                    0.15        0.787
  Japanese                                                   0.19        0.757
  South Asian                                                0.35        0.702
  Other Asian                                                0.012       0.736
  Other Race                                                 0.0051      0.555
  American Indian/Alaskan Native                             0.69        0.873
                                                                         
  **Surveillance Epidemiology and End Reporting Registry**               
  Alaska Natives                                             0.63        0.598
  Atlanta                                                    0.47        1.098
  California excl SF/SJM/LA                                  0.05        1.173
  Connecticut                                                --          1
  Detroit                                                    0.57        1.06
  Greater Georgia                                            0.004       1.312
  Hawaii                                                     0.11        1.32
  Iowa                                                       0.70        1.043
  Kentucky                                                   0.0099      1.286
  Los Angeles                                                0.77        1.028
  Louisiana                                                  0.03        1.258
  New Jersey                                                 0.22        1.108
  New Mexico                                                 0.38        1.158
  Rural Georgia                                              0.13        0.503
  San Francisco-Oakland                                      0.61        1.06
  San Jose-Monterey                                          0.95        0.99
  Seattle                                                    0.18        1.154
  Utah                                                       0.05        1.397
                                                                         
  **Income**                                                             
  \<\$50,000                                                 0.71        1.019
  \$50,000--74,000                                           --          1
  ≥75,000                                                    0.19        0.93
                                                                         
  **Marital status**                                                     
  Divorced                                                   \<0.0001    1.301
  Married                                                    --          1
  Separated                                                  0.23        1.239
  Single                                                     0.0015      1.211
  Unknown                                                    0.54        1.062
  Domestic partner                                           0.84        1.221
  Widowed                                                    \<0.0001    1.292
                                                                         
  Tumor size                                                 \<0.0001    1.016
                                                                         
  **Tumor stage**                                                        
  T1                                                         --          1
  T2                                                         0.01        1.107
                                                                         
  **Insurance**                                                          
  Insured                                                    --          1
  Medicaid                                                   \<0.0001    1.385
  Uninsured                                                  0.69        1.065
  Unknown                                                    0.67        0.887
                                                                         
  **Lateral location**                                                   
  Bronchus, left                                             0.29        0.468
  Bronchus, right                                            0.87        0.891
  Bronchus, unknown                                          0.89        0.872
  Left lower                                                 0.36        0.952
  Left upper                                                 0.92        1.004
  Left NOS                                                   0.14        1.454
  Left overlapping                                           0.90        1.055
  Right lower                                                0.0089      1.132
  Right middle                                               0.09        0.869
  Right upper                                                --          1
  Right NOS                                                  0.84        0.946
  Right overlapping                                          0.75        0.926
                                                                         
  **Histology---no. (%)**                                                
  Adenocarcinoma                                             --          1
  Adenosquamous                                              0.16        1.15
  Large cell                                                 0.0011      1.381
  Non-small cell                                             0.001       1.317
  Other                                                      0.78        0.942
  Squamous                                                   \<0.0001    1.236
                                                                         
  **Grade**                                                              
  Moderately, II                                             \<0.0001    1.621
  Poorly, III                                                \<0.0001    1.846
  Undifferentiated, IV                                       0.0019      1.572
  Unknown                                                    \<0.0001    1.707
  Well, I                                                    --          1
                                                                         
  **Surgical procedure**                                                 
  (Bi)Lobectomy                                              --          1
  Pneumonectomy                                              \<0.0001    1.782
  Segmentectomy                                              0.009       1.235
  Sub-lobar resection, NOS                                   0.10        1.442
  Wedge                                                      \<0.0001    1.301
                                                                         
  Radiation post-operative                                   \<0.0001    1.36
                                                                         
  Number of nodes examined                                   \<0.0001    0.984
                                                                         
  **Year of diagnosis**                                                  
  2007                                                       --          1
  2008                                                       0.03        0.904
  2009                                                       0.13        0.929
  2010                                                       0.0016      0.832
  2011                                                       0.44        0.949
  2012                                                       0.0004      0.661

LCSS in the ESR Population {#S3-5}
--------------------------

Multivariate analysis for LCSS for ESR population can be seen in Table [5](#T5){ref-type="table"}. Age (*p* \< 0.0001, HR = 1.023) and male sex (*p* \< 0.0001, HR = 1.393) were significantly associated with LCSS. LCSS was not significantly associated with race or income. As compared to Connecticut, worse LCSS was noted in Greater Georgia, Kentucky, and Louisiana. Insured patients had a better LCSS than those on Medicaid (*p* \< 0.0001, HR = 1.445). Married patients had a better LCSS than divorced (*p* \< 0.0004, HR = 1.301) and widowed (*p* \< 0.0036, HR = 1.200). Increasing tumor size (*p* \< 0.0001, HR = 1.020) and T2 vs T1 (*p* = 0.0003, HR = 1.213) were associated with a worse LCCS. Only the right middle lobe location was associated with LCSS (*p* \< 0.0469, HR = 0.803). As compared to patients with adenocarcinoma, NSCLC-NOS (*p* \< 0.002, HR = 1.382) and large cell carcinoma (*p* = 0.0003, HR = 1.543) were correlated with a worse LCSS. Using well-differentiated tumors as a reference, all other tumor grades were associated with a worse LCSS (HR = 1.693--2.171). Segmentectomies (*p* \< 0.0065, HR = 1.329), pneumonectomies (*p* = 0.0027, HR = 1.781), and wedge resections (*p* \< 0.0001, HR = 1.353) were associated with a worse LCSS than (bi)lobectomies. Patients who received radiation (*p* \< 0.0001, HR = 1.556) experienced worse LCSS. Number of nodes examined was associated with better LCSS (*p* \< 0.0001, HR = 0.978). Compared to year 2007, those patients diagnosed in all other years, except for 2011 had a significantly better LCSS. OS and LCSS by marital status can be seen in Figures [3](#F3){ref-type="fig"}A,B.

###### 

Multivariate analysis for lung cancer-specific survival in early-stage resectable population.

  Early-stage resectable (*N* **=** 17,931)                  *p*-Value   Hazard ratio
  ---------------------------------------------------------- ----------- --------------
  Age---years                                                \<0.0001    1.023
                                                                         
  **Sex**                                                                
  Female                                                                 1
  Male                                                       \<0.0001    1.393
                                                                         
  **Race**                                                               
  White Hispanic                                             0.26        0.877
  White non-Hispanic                                         --          1
  Black                                                      0.54        0.949
  Chinese                                                    0.41        0.839
  Japanese                                                   0.07        0.534
  South Asian                                                0.76        0.872
  Other Asian                                                0.06        0.745
  Other Race                                                 0.10        0.655
  American Indian/Alaskan Native                             0.14        0.348
                                                                         
  **Surveillance Epidemiology and End Reporting Registry**               
  Alaska Natives                                             0.44        2.575
  Atlanta                                                    0.82        0.96
  California excl SF/SJM/LA                                  0.17        1.183
  Connecticut                                                --          1
  Detroit                                                    0.36        1.13
  Greater Georgia                                            0.02        1.344
  Hawaii                                                     0.60        1.134
  Iowa                                                       0.16        1.218
  Kentucky                                                   0.0025      1.473
  Los Angeles                                                0.41        1.112
  Louisiana                                                  0.0065      1.457
  New Jersey                                                 0.55        1.07
  New Mexico                                                 0.05        1.497
  Rural Georgia                                              0.36        0.585
  San Francisco-Oakland                                      0.92        0.985
  San Jose-Monterey                                          0.65        0.909
  Seattle                                                    0.76        1.046
  Utah                                                       0.31        1.278
                                                                         
  **Income**                                                             
  \<\$50,000                                                 0.17        0.912
  \$50,000--74,000                                           --          1
  ≥75,000                                                    0.62        0.965
                                                                         
  **Marital status**                                                     
  Divorced                                                   0.0004      1.272
  Married                                                    --          1
  Separated                                                  0.96        0.988
  Single                                                     0.06        1.16
  Unknown                                                    0.61        0.935
  Domestic partner                                           0.97        0
  Widowed                                                    0.0036      1.2
                                                                         
  Tumor size                                                 \<0.0001    1.02
                                                                         
  Tumor stage                                                            
  T1                                                         --          1
  T2                                                         0.0003      1.213
                                                                         
  **Insurance**                                                          
  Insured                                                                1
  Medicaid                                                   \<0.0001    1.445
  Uninsured                                                  0.89        1.029
  Unknown                                                    0.84        0.932
                                                                         
  **Lateral location**                                                   
  Bronchus, left                                             0.92        0
  Bronchus, right                                            0.63        1.41
  Bronchus, unknown                                          0.97        0
  Left lower                                                 0.68        0.971
  Left upper                                                 0.91        0.994
  Left NOS                                                   0.42        1.334
  Left overlapping                                           0.77        1.16
  Right lower                                                0.09        1.111
  Right middle                                               0.05        0.803
  Right upper                                                --          1
  Right NOS                                                  0.86        0.941
  Right overlapping                                          0.91        0.966
                                                                         
  **Histology---no. (%)**                                                
  Adenocarcinoma                                             --          1
  Adenosquamous                                              0.43        1.106
  Large cell                                                 0.0003      1.543
  Non-small cell                                             0.002       1.382
  Other                                                      0.87        0.957
  Squamous                                                   0.06        1.104
                                                                         
  **Grade**                                                              
  Moderately, II                                             \<0.0001    1.81
  Poorly, III                                                \<0.0001    2.171
  Undifferentiated, IV                                       0.005       1.693
  Unknown                                                    \<0.0001    2.013
  Well, I                                                    --          1
                                                                         
  **Surgical procedure**                                                 
  (Bi)Lobectomy                                              --          1
  Pneumonectomy                                              0.003       1.781
  Segmentectomy                                              0.007       1.329
  Sub-lobar resection, NOS                                   0.08        1.61
  Wedge                                                      \<0.0001    1.353
                                                                         
  Radiation post-operative                                   \<0.0001    1.556
                                                                         
  Number of nodes examined                                   \<0.0001    0.978
                                                                         
  **Year of diagnosis---no. (%)**                                        
  2007                                                       --          1
  2008                                                       0.02        0.875
  2009                                                       0.02        0.857
  2010                                                       0.001       0.779
  2011                                                       0.06        0.842
  2012                                                       0.003       0.612

![**(A,B)** Multivariable adjusted overall survival and lung cancer-specific survival in the early-stage resectable population by marital status.](fonc-08-00146-g003){#F3}

90-Day Mortality Analysis {#S3-6}
-------------------------

Multivariate analysis for 90-day OS for TS population can be seen in Table [6](#T6){ref-type="table"}. Age (*p* \< 0.0001, HR = 1.045) and male sex (*p* \< 0.0001, HR = 1.547) were significantly associated with 90-day OS. 90-day mortality was the same in all ethnic groups. Higher median income (\>\$75,000) was associated with a better survival. As compared to Connecticut, worse survival was noted in Louisiana and Utah. Insured patients had a better 90-day OS than those on Medicaid (*p* = 0.0005, HR = 1.359) and those with unknown insurance (*p* = 0.0003, HR = 2.774). Married patients had a better OS than single (*p* = 0.0188, HR = 1.239) and unmarried/domestic partner patients (*p* = 0.0310, HR = 3.523). Right bronchus (*p* = 0.0001, HR = 2.652), bronchus unknown (*p* = 0.0012, HR = 6.926), and right lower lobe (*p* \< 0.0001, HR = 1.386) were associated with worse 90-day mortality than the right upper lobe location. As compared to Stage I, Stages II--IV were associated with a worse OS with a progressively increasing HRs (all *p* \< 0.0001, HR = 1.607--4.381). As compared to patients with adenocarcinoma, NSCLC-NOS (*p* \< 0.0034, HR = 1.460), other (*p* \< 0.0001, HR = 2.334), and squamous cell carcinoma (*p* \< 0.0001, HR = 1.436) had a higher risk of 90-day mortality. Using well-differentiated tumors as a reference, 90-day mortality was higher in patients having poorly differentiated, undifferentiated, and unknown differentiated tumors. Pneumonectomies were associated with a significantly higher 90-day mortality than all other resection types (*p* = 0.0281 to \<0.0001, HR = 0.418--0.775), except for sub-lobar, NOS which had a higher mortality (*p* = 0.0012, HR = 1.885). Patients who received radiation experienced a significantly lower 90-day mortality (*p* \< 0.0001, HR = 0.217). Number of nodes examined was associated with better OS (*p* = 0.0001, HR = 0.984), but number of nodes positive and lymph node density were associated with worse OS. Similar 90-day mortality was noted to 2007 for years 2008--2012.

###### 

Multivariate analysis for 90-day overall survival in TP.

  All surgical (*N* **=** 35,689)                            *p*-Value   Hazard ratio
  ---------------------------------------------------------- ----------- --------------
  Age---years                                                \<0.0001    1.045
                                                                         
  **Sex**                                                                
  Female                                                     --          1
  Male                                                       \<0.0001    1.547
                                                                         
  **Race**                                                               
  White Hispanic                                             0.09        1.219
  White non-Hispanic                                         --          1
  Black                                                      0.96        1.005
  Chinese                                                    0.58        0.861
  Japanese                                                   0.11        0.532
  South Asian                                                0.58        0.672
  Other Asian                                                0.21        0.772
  Other Race                                                 0.11        0.563
  American Indian/Alaskan Native                             0.11        1.861
                                                                         
  **Surveillance Epidemiology and End Reporting Registry**               
  Alaska Natives                                             0.80        0.813
  Atlanta                                                    0.34        1.212
  California excl SF/SJM/LA                                  0.51        1.098
  Connecticut                                                --          1
  Detroit                                                    0.41        0.858
  Greater Georgia                                            0.10        1.301
  Hawaii                                                     0.91        1.036
  Iowa                                                       0.91        1.022
  Kentucky                                                   0.09        1.317
  Los Angeles                                                0.13        1.271
  Louisiana                                                  0.04        1.428
  New Jersey                                                 0.39        1.134
  New Mexico                                                 0.25        1.332
  Rural Georgia                                              0.16        1.854
  San Francisco-Oakland                                      0.96        0.99
  San Jose-Monterey                                          0.79        1.068
  Seattle                                                    0.10        1.347
  Utah                                                       0.01        1.735
                                                                         
  **Income**                                                             
  \<\$50,000                                                 0.07        1.16
  \$50,000--75,000                                           --          1
  \>75,000                                                   0.01        0.782
                                                                         
  **Tumor stage**                                                        
  I                                                          --          1
  II                                                         \<0.0001    1.607
  III                                                        \<0.0001    2.238
  IV                                                         \<0.0001    4.381
                                                                         
  **Marital status**                                                     
  Divorced                                                   0.78        0.974
  Married                                                    --          1
  Separated                                                  0.88        0.954
  Single (never married)                                     0.02        1.239
  Unknown                                                    0.52        1.1
  Unmarried or domestic partner                              0.03        3.523
  Widowed                                                    0.13        1.127
                                                                         
  **Insurance**                                                          
  Insured                                                    --          1
  Medicaid                                                   0.0005      1.359
  Uninsured                                                  0.24        1.279
  Unknown                                                    0.0003      2.774
                                                                         
  **Lateral location**                                                   
  Bronchus, left                                             0.51        0.786
  Bronchus, right                                            0.0001      2.652
  Bronchus, unknown                                          0.0012      6.926
  Left lower                                                 0.37        0.917
  Left upper                                                 0.43        1.063
  Left NOS                                                   0.01        1.628
  Left overlapping                                           0.34        1.369
  Lung, NOS                                                  0.0004      2.37
  Right lower                                                \<0.0001    1.386
  Right middle                                               0.80        0.965
  Right upper                                                --          1
  Right NOS                                                  0.004       1.587
  Right overlapping                                          \<0.0001    2.725
                                                                         
  **Histology---no. (%)**                                                
  Adenocarcinoma                                             --          1
  Adenosquamous                                              0.79        1.044
  Large cell                                                 0.42        1.139
  Non-small cell                                             0.003       1.46
  Other                                                      \<0.0001    2.334
  Squamous                                                   \<0.0001    1.436
                                                                         
  **Grade**                                                              
  Moderately, II                                             0.23        1.134
  Poorly, III                                                0.003       1.378
  Undifferentiated, IV                                       0.005       1.745
  Unknown                                                    0.0004      1.584
  Well, I                                                    --          1
                                                                         
  **Surgical procedure**                                                 
  Sub-lobar resection, NOS                                   0.001       1.885
  (Bi)lobectomy                                              \<0.0001    0.475
  Pneumonectomy                                              --          1
  Segmentectomy                                              \<0.0001    0.418
  Wedge                                                      0.03        0.775
                                                                         
  Radiation post-operative                                   \<0.0001    0.217
                                                                         
  Number of nodes examined                                   0.0001      0.984
                                                                         
  Number of nodes positive                                   0.51        0.986
                                                                         
  Node density                                               0.08        1.352
                                                                         
  **Year of diagnosis---no. (%)**                                        
  2007                                                       --          1
  2008                                                       0.35        1.087
  2009                                                       0.41        1.077
  2010                                                       0.82        1.021
  2011                                                       0.96        0.996
  2012                                                       0.53        1.065

Characteristics Associated With Nodal Positivity {#S3-7}
------------------------------------------------

In Table [7](#T7){ref-type="table"}, a multivariate analysis was performed for the risk of having nodal positivity in patients undergoing a definitive surgical procedure with a T1--T2 tumor \<2 cm and at least one lymph node examined. The results were adjusted for type of surgical resection. Age (*p* \< 0.0001, HR = 1.036) and male sex (*p* \< 0.0001, HR = 1.386) were significantly associated with positive nodes. Positive nodes were not associated with any ethnic or income group. As compared to Connecticut, a greater risk of positive nodes was found in Greater Georgia, Hawaii, and Utah. T2 tumor had a higher risk of positive nodes than T1 tumors (*p* = 0.0004, HR = 1.289). Patients without a married partner (*p* \< 0.0033, HR = 1.376) or without insurance (*p* \< 0.0003, HR = 1.376) were more likely to have positive nodes. Right lower lobe location (*p* \< 0.0353, HR = 1.185) was associated with a higher likelihood of positive nodes than the right upper lobe location. As compared to patients with adenocarcinoma, adenosquamous cell (*p* \< 0.0316, HR = 1.416), large cell (*p* \< 0.0252, HR = 1.426), and squamous cell carcinomas (*p* = 0.0437, HR = 1.149) had a higher risk of having positive nodes. Using well-differentiated tumors as a reference, nodal positivity was higher in patients having poorly differentiated (*p* \< 0.0001, HR = 2.157), moderately differentiated (*p* \< 0.0001, HR = 1.784), and unknown differentiated tumors (*p* \< 0.0001, HR = 1.802). Number of nodes examined was not associated with nodal positivity. Nodal positivity was less likely in years 2010--2012 (*p* = 0.0427--0.0027), with a progressively decreased HR (0.821--0.0027).

###### 

Multivariate analysis for node positivity by various factors for T1--T2 tumors \<2 cm with at least one node removed, adjusted for type of surgical resection.

  All surgical patients with T1 or T2 tumors **\<**2 cm (*N* **=** 7,580)   *p*-Value   Hazard ratio
  ------------------------------------------------------------------------- ----------- --------------
  Age---years                                                               \<0.0001    1.036
                                                                                        
  **Sex**                                                                               
  Female                                                                    --          1
  Male                                                                      \<0.0001    1.386
                                                                                        
  **Race**                                                                              
  White Hispanic                                                            0.99        0.998
  White non-Hispanic                                                        --          1
  Black                                                                     0.89        0.986
  Chinese                                                                   0.06        0.488
  Japanese                                                                  0.32        0.699
  South Asian                                                               0.70        0.675
  Other Asian                                                               0.31        0.808
  Other Race                                                                0.38        0.754
  American Indian/Alaskan Native                                            0.09        1.219
                                                                                        
  **Surveillance Epidemiology and End Reporting Registry**                              
  Alaska Natives                                                            0.97        1
  Atlanta                                                                   0.38        1.19
  California excl SF/SJM/LA                                                 0.36        1.13
  Connecticut                                                               --          1
  Detroit                                                                   0.59        0.912
  Greater Georgia                                                           0.02        1.415
  Hawaii                                                                    0.05        1.83
  Iowa                                                                      0.95        0.988
  Kentucky                                                                  0.41        1.144
  Los Angeles                                                               0.77        0.953
  Louisiana                                                                 0.49        1.136
  New Jersey                                                                0.93        1.012
  New Mexico                                                                0.43        1.256
  Rural Georgia                                                             0.90        1.099
  San Francisco-Oakland                                                     0.97        1.008
  San Jose-Monterey                                                         0.54        0.837
  Seattle                                                                   0.11        1.323
  Utah                                                                      0.04        1.705
                                                                                        
  **Income**                                                                            
  \<\$50,000                                                                0.10        1.151
  \$50,000--75,000                                                          --          1
  \>75,000                                                                  0.39        0.922
                                                                                        
  Tumor size                                                                            1.008
                                                                                        
  **Tumor stage**                                                                       
  T2 vs T1                                                                  0.0004      1.289
                                                                                        
  **Marital status**                                                                    
  Other                                                                     0.003       1.191
  Married                                                                   --          1
                                                                                        
  **Insurance**                                                                         
  Insured                                                                   --          1
  Other                                                                     0.0003      1.376
                                                                                        
  **Lateral location**                                                                  
  Bronchus, left                                                            0.95        1.047
  Bronchus, right                                                           0.95        1
  Left lower                                                                0.90        0.989
  Left upper                                                                0.62        0.965
  Left NOS                                                                  0.83        1.088
  Left overlapping                                                          0.95        1.047
  Lung, NOS                                                                 0.99        1
  Right lower                                                               0.04        1.185
  Right middle                                                              0.08        0.782
  Right upper                                                               --          1
  Right NOS                                                                 0.30        0.653
  Right overlapping                                                         0.87        1.087
                                                                                        
  **Histology---no. (%)**                                                               
  Adenocarcinoma                                                            --          1
  Adenosquamous                                                             0.03        1.419
  Large cell                                                                0.03        1.426
  Non-small cell                                                            0.46        1.113
  Other                                                                     0.11        0.199
  Squamous                                                                  0.04        1.149
                                                                                        
  **Grade**                                                                             
  Moderately, II                                                            \<0.0001    1.784
  Poorly, III                                                               \<0.0001    2.157
  Undifferentiated, IV                                                      0.89        1.047
  Unknown                                                                   \<0.0001    1.802
  Well, I                                                                   --          1
                                                                                        
  Number of nodes examined                                                  0.28        0.995
                                                                                        
  **Year of diagnosis---no. (%)**                                                       
  2007                                                                      --          1
  2008                                                                      0.70        0.971
  2009                                                                      0.71        0.969
  2010                                                                      0.04        0.821
  2011                                                                      0.003       0.679
  2012                                                                      0.003       0.519

Discussion {#S4}
==========

The purpose of our investigation was to assess difference in outcomes (OS and 30/90 day mortality), presentation, and treatment in nine different ethnic groups who underwent surgical resection of NSCLC. As compared to Whites, the unadjusted OS and LCSS was significantly greater in the Chinese, South Asian, Other Asian, and the Other Race groups. After multivariable adjustment, OS was significantly better than Whites in all groups except for AI/ANs, Japanese, Blacks, and Hispanics who had a similar OS. Despite presenting with higher stage tumors, lower median incomes, lower rates of insurance, less nodes examined, less grade 1 tumors, and lower marriage rates, the OS and LCSS of the Black group were not significantly different than that of the Whites. In comparison to the White group, Hispanics had a similar LCSS, but had an improved OS despite having a higher unadjusted 30-day mortality. Although Hispanics presented with a lower percentage of Stage I patients, lower marriage rates, less nodes examined, and lower rates of insurance, they presented with many better prognostic features compared to the Whites including higher income, lower tumor grades, younger age, higher percentage of female patients, and a higher percentage of adenocarcinomas. The Chinese and Other Asian groups were more likely to receive a (bi)lobectomy than the Whites, but the other ethnic groups largely did not differ in the type of surgical procedure. The reason for the higher 30-day mortality (unadjusted) in the Hispanic population is currently unknown, but the all other populations had a similar or better (Japanese or Other Race) 30-day survival to the White population. Although the unadjusted 90-day mortality was lower in the Other Asian and Other Race populations, there was no difference between the other ethnic groups and the Whites. However, the MVA demonstrated that there was no significant difference between the ethnic groups as compared to Whites. It should be noted that we included stage IV patients in this analysis of patients undergoing a definitive surgical procedure because a satellite nodule in a different lobe of the ipsilateral lung was classified by the AJCC staging as metastatic until 2010 when the new AJCC seventh edition classified this situation as T4 ([@B11]). The percentage of each ethnic group undergoing a definitive surgical procedure for Stage IV disease varied from 4.5 to 9.8%. Only the Hispanic group had significantly different percentage of Stage IV patients than the White patients (9.8% of Hispanics vs 6.9% of Whites). Two thousand five hundred sixty three patients with Stage IV tumors underwent a definitive surgical procedure. One thousand six hundred twenty-seven patients were classified as having tumors nodules in different ipsilateral lobes during the years 2007--2009. One thousand one hundred twenty-nine underwent a sub-lobar resection (966 wedge, 92 segmentectomy, and 71 sub-lobar, NOS). Although some patients may have undergone a diagnostic wedge procedure, we assume that most of the remaining patients who did not have tumor nodules in different ipsilateral lobes (*N* = 936) may have been found to have metastatic disease shortly after their surgical procedure. However, the performance of staging investigations and their timing in relation to surgical procedures is not available in SEER. Nevertheless, after removing the patients who would now be re-classified as having Stage III NSCLC, the numbers were too small for further characterization of these patients by ethnicity.

It is interesting to note that the multivariable analyses for OS in the TS and ESR, and LCSS in the ESR populations yielded similar results to the multivariable analyses for OS in our companion manuscript containing two different lung cancer populations (all patients presenting with NSCLC and those presenting with Stage IV disease). In all four lung cancer populations in both manuscripts, well-established risk factors ([@B12], [@B13]) for OS and LCSS were noted in all multivariable analyses including tumor size, stage, differentiation, gender, age, and *t*-stage. After adjustment for histolopathologic, gender, age, treatment, and marital variables, all ethnicities in all analyses had similar or significantly better OS and LCSS (ESR group only) compared to the White group. Adenocarcinoma was uniformly associated with a better OS. A consistently lower OS and LCSS were noted for all four lung cancer populations in Greater Georgia, Louisiana, and Kentucky. Similarly, patients in California and Iowa had poorer outcomes except for OS in the Stage IV population in California and OS in the ESR group in Iowa. The reason for the consistently poor outcomes across all stages and presentations in these registries is currently not known, but we believe that the number physician per 100,000 may be a factor because all five states rank in the bottom half of states in terms of the density of total active physicians as well as primary care physicians ([@B14]). Of interest, the highly significantly survival decrement (*p* \< 0.0001) for tumor location in the mainstem bronchi in the companion manuscript was less significant in the surgical patients where only the right mainstem (*p* = 0.01) remained significant for OS in the TS group. There was no OS or LCSS decrement noted in the ESR population for the mainstem bronchi location. However, there was only a small number of tumors associated with the mainstem bronchi (*N* = 30) in the ESR group. We hypothesize that surgery neutralizes the effects of mainstem bronchi locations because this modality effectively eradicates a location that can cause obstructive pneumonias in a compromised patient group. Interestingly, although the companion paper noted that both lower lobe locations were noted to be associated with decreased OS, only the right lower lobe location was noted to be associated with worse OS in the surgical patients. The association of the lower lobes with worse outcomes has been noted in other investigations ([@B15], [@B16]). Our analysis demonstrates that the worse OS survival in patients having tumor located in the right lower lobe may be due to an increased risk of nodal involvement. Prognosis in all lung cancer populations was improved by being married, not having Medicaid, and being insured, but unlike the previous analysis, income was not correlated with LCSS and OS in the surgical patients in this investigation with the exception of borderline worse of OS in the TS population for those individuals with a median household income of \<\$50,000 (*p* = 0.0457). In addition, all lung cancer populations were noted to have a general improvement in OS during the years of this study. The improvement in the surgical populations may have been due to variables that are not contained within SEER such as improved staging, increased use of chemotherapy, and better post-operative care. However, the improved OS in the ESR group would argue against the increased use of adjuvant therapy because chemotherapy would be less likely to be used in this group ([@B17], [@B18]). Likewise, it may be argued that better post-operative care did not contribute to the better OS of the TS population because the 90-day mortality did not improve during the years of this study.

This manuscript was able to assess some treatment-related factors because SEER-18 does contain some variables related to radiation and surgery. Patients receiving pre-operative radiation were excluded because it was felt that this treatment could obscure/improve histolopathologic variables. Because SEER-18 does not contain information pertaining to chemotherapeutic treatment, we deliberately decided to separately assess a surgical sub-group of patients with tumors 4 cm or less without nodal involvement because these patients would be unlikely to receive chemotherapy ([@B17], [@B18]). Furthermore, we decided to investigate LCSS as well in this group of early-stage patients because of their relatively high likelihood of surviving lung cancer and possibly succumbing to other smoking-related causes. Worse OS and LCSS were consistently noted after a pneumonectomy despite multivariable analyses that accounted for histopathologic, patient, and tumor location variables. The adverse survival of patients undergoing a pneumonectomy was identified in recent retrospective study that demonstrated that that the lower survival may be due to an increased risk of distal metastases ([@B19]). Although the immune effects of a larger lung cancer procedures such as pneumonectomy as compared to (bi)lobectomy and sub-lobar resections is not known, it has been shown that transthoracic surgery for esophageal cancer as compared to smaller and less invasive surgical procedures (gastrectomy for cancer and cholecystomy for benign gallstones) has been associated with a transient immunosuppression (increased T-cell apoptosis and decreased T-cell cytokine production) during post-operative days 1--3 ([@B20]). Interestingly, a different research group noted that both transhiatal and transthoracic esophagectomies were associated with reduced TH1-type cytokine production on post-operative day 1, but depression of Th2-type cytokine was more profound with the latter procedure ([@B21]). In both surgical populations, the number of nodes examined was strongly correlated with OS and LCSS and was similarly noted in a past SEER analysis ([@B22]). The better outcomes associated with an increasing number of nodes examined may be due to the removal of microscopic disease that may or may not be recognized (especially in the ESR group) by routine pathologic methods ([@B23]), but because there is no OS with mediastinal lympadenectomy as compared to nodal sampling ([@B24]), one might infer that the beneficial effects of lymph node examination may be due to upstaging cancers that would otherwise be classified as node negative. Post-operative radiation was associated with poorer OS and LCSS. Although past retrospective analyses have demonstrated a possible survival benefit for radiation therapy in patients with N2 disease ([@B25], [@B26]), others have not ([@B27]). However, there has been general agreement that post-operative radiation results in a survival decrement in patients with N0 and N1 disease ([@B25], [@B26]). A recent retrospective investigation demonstrated that there was an OS benefit for post-operative radiation therapy for patients who experience a positive resection margin for all nodal stages ([@B28]). We would assume that the patients who receive post-operative radiation therapy for nodal stages N0--N1 during the years of our study had a positive margin, but SEER does not have information concerning margin status, and our results show a strongly negative effect of radiation on OS and LCSS in the surgical patients. Although there may be negative selection factors (i.e., positive margin, lymphatic, and/or vascular invasion) in the patients receiving radiation, it may be that radiation therapy has no efficacy and could possibly only have deleterious effects in the post-operative setting, especially in those with N0--N1 disease.

The MVA for 90-day OS revealed that mortality was not related to ethnicity, but was significantly correlated with single/unmarried partner status, Medicaid or unknown insurance, and income. Nevertheless, several known histopathologic and patient prognostic factors associated with aggressive disease/poor outcomes predicted 90-day mortality included increasing patient age, male sex, tumor differentiation, stage, and non-adenocarcinoma histology and suggest that aggressive tumor spread and/or understaging at the time of resection may be the reasons for poor early survival. However, because financial and partnership variables did affect 90-day mortality, one may conclude that patients may be able to improve their short-term survival by better economic and emotional support. Of interest, even after accounting for histopathologic characteristics, tumor locations in the right mainstem bronchus and right lower lobe were associated with a decrement in OS. We hypothesize that operative complications associated with these locations may be a reason why these sites adversely affect OS in the TS and ESR populations. Treatment-related factors related to an increased mortality included the performance of a pneumonectomy and less nodes examined. We decided to include radiation in this analysis because we felt that radiation could possible result in an increased early mortality. Interestingly, radiation was strongly associated with an improved 90-day survival which may be due to patient selection factors which are not acknowledged by SEER including a better ECOG performance status, less co-morbidities, and lower risk of immediate post-operative infections. Early mortality did not improve during the years of our investigation suggesting that post-operative care was not associated with the improved outcomes in surgical patients.

The decision to assess tumors generally considered eligible for a sub-lobar resection (T1--T2 tumors \<2 cm in size) was made in order to assess which patients would benefit from a lymphadenectomy. Not surprisingly, nodal positivity was associated with known prognostic factors including advanced age, male sex, *t*-stage, aggressive histologies (adenosquamous, large cell, and squamous carcinomas), and tumor differentiation. Importantly, it should be noted that ethnicity was not associated with an increased risk of having positive nodes. Although income was not associated with nodal positivity, not being insured and not being married were both strongly associated with having node involvement. Because this analysis revealed that the right lower lobe location was associated with positive nodes, we believe that this may be a reason why this location is associated with a lower OS in both the TS and ESR populations.

We originally performed this analysis to assess the effects of the presentation and outcome differences by ethnicity as compared to Whites in patients undergoing surgical resection for lung cancer. In comparison to White patients, OS, LCSS, and 90-day mortality were similar or better in all ethnic groups for all three analyses. Median household income was largely not associated with OS or LCSS in the TS and ESR patients, but was strongly associated with 90-day mortality. Because this variable was assigned to patients based upon the median county income, we assume this variable may have adversely affected 90-day survival due to the hospital care received in more wealthy and less affluent areas. Of importance, Medicaid insurance and not being married were associated with lower OS and LCSS as well as an increased risk of 90-day mortality. We feel that not Medicaid insurance is more likely to represent an individual's economic status and demonstrates the importance of having insurance. However, of great interest, is that having Medicaid and not being married are factors that were also associated with an increased risk of nodal involvement. This suggests that economic and psychological factors can possibly be associated with lung cancer biology. Lower socioeconomic status may affect tumor biology through poor nutrition ([@B29]). Recently, it was noted that unmarried lung cancer patients had a greater incidence of depression, less social support, and a survival decrement ([@B30]), and that the survival decrement noted in patients with new-onset or persistent depression may be more so in early-stage (Stages I--II) than in patients with more advanced stages ([@B31]). We feel that our results suggest that the economic effects of not having insurance and not being married are associated with real changes in tumor biology and aggressiveness.

It should be noted that the SEER database lacks may variables that would have been useful for our analysis including smoking history, body mass index, ECOG performance status, lymphatic and/or vascular invasion, patient co-morbidities, chemotherapy administration, type of surgical procedure (i.e., VATS, robotic surgery, and traditional thoracotomy), radiation dose, and radiation field arrangement. However, we have no reasons to think that any of these variables would have influenced our outcomes because we could account for median household income, type of insurance, and most major histopathologic variables.

In summary, the main purpose of our investigation was to assess difference in outcomes (OS and 30/90 day mortality), presentation, and treatment in nine different ethnic groups who underwent surgical resection of NSCLC. As a secondary aim, we also wanted to assess whether tumor biology (nodal involvement) varied by ethnicity. Even in the analyses that were not adjusted for treatment, histopathologic, patient, and marital factors; Blacks and Hispanics had the same OS and LCSS as the White group. We did not find disparities due to ethnicity in patients undergoing surgical resection for NSCLC, but noted that the disparities may be due to having Medicaid insurance and not being married. Because having Medicaid insurance and not being married were associated with lower OS, LCSS and 90-day OS as well as nodal positivity, we feel that economic and psychosocial variables may play a role in the biological aggressiveness of early-stage lung cancer patients undergoing resection in addition to standard histopathologic and treatment variables. Although marriage was equally as important as socioeconomic factors in our assessment, a study from an earlier time period (1989--2003) suggested that lower socioeconomic status was an independent prognostic factor, but marriage was note ([@B32]). However, this past investigation by Ou et al. also noted that race was not a prognostic factor in multivariate modeling.

Conclusion {#S5}
==========

In TS and ESR populations, OS was not different in the two largest ethnic groups (Black, Hispanic) as compared to Whites, but was related to single/divorced status, medicaid insurance, and income (TS population only). Nodal positivity was associated with patients who did not have a married partner or insurance suggesting that these factors may impact disease biology. Economic and psychosocial variables may play a role in survival of early-stage lung cancer in addition to standard histopathologic and treatment variables.
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